Recent Updates
Recently added Catalysts

Reference Listed Drug

Phase 1

Inflammation Following Ocular Surgery | Small molecule | Ophthalmology |Novartis AG|Last Updated: Nov 6, 2019

Target and mechanism

ModalitySmall molecule

Also known as Reference Listed Drug (RLD)

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedACTIVE_CONTROLLED
Total Trials1
Total Enrollment381

FDA Designations

No designations recorded

Clinical trial landscape

Reference Listed Drug · 1 trial · 1 indication

Phase 1 1
NCT03531697Study of Loteprednol Etabonate in Adults Undergoing Bilateral Cataract SurgeryInflammation Following Ocular Surgery
COMPLETED381 Analytics
PHASE1COMPLETED
Study of Loteprednol Etabonate in Adults Undergoing Bilateral Cataract Surgery
Inflammation Following Ocular SurgeryUnlock trial analytics

Study Endpoints

Primary Endpoints

Pharmacokinetic (PK) assessed by Area Under the Curve (AUC)
upon study completion, up to 1 year

PK for loteprednol etabonate concentrations in aqueous humor. Area under the concentration versus time curve.

Pharmacokinetic (PK) assessed by rate of drug absorption (Cmax)
upon study completion, up to 1 year

PK for loteprednol etabonate concentrations in aqueous humor. Maximum observed mean concentration in aqueous humor over the time span specified.

Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingSINGLE
ModelCROSSOVER
PurposeOTHER

Treatment Arms

ArmTypeDescription
Generic Loteprednol Etabonate - RLDEXPERIMENTALPeriod 1: Generic Loteprednol Etabonate - Period 2 (Cross-Over): Reference Listed Drug (RLD)
RLD - Generic Loteprednol EtabonateACTIVE_COMPARATORPeriod 1: Reference Listed Drug (RLD) - Period 2 (Cross-Over): Generic Loteprednol Etabonate

Interventions

NameTypeDescription
Generic Loteprednol EtabonateDRUGDrug
Reference Listed Drug (RLD)DRUGDrug
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * Subjects must have a need for cataract surgery in both eyes and can be dosed in the surgical eyes. * Non-pregnant, non-lactating females, or women who are post-menopausal (defined as at least 12 months natural, spontaneous amenorrhea), or are naturally or surgically sterile (h...

Countries:Canada
Unlock Eligibility Criteria